US-based medical diagnostics firm Kypha has purchased Irish diagnostics platform and contract development company Biosensia for an undisclosed amount.
Part of the NovaUCD innovation community, Biosensia focuses on developing and manufacturing the RapiPlex diagnostic device and tests for laboratory use. RapiPlex is designed to deliver both quantitative and qualitative results.
Kypha said that the deal forms part of its strategy to offer reliable immune status results in virtually all settings, including acute hospital care and home use. It expects the acquisition to bolster its product commercialisation.
Kypha’s portfolio includes a portable testing platform called Compact for the quantitative measurement of complement activation biomarkers in a blood sample in laboratory or at point-of-care.
The combination of the companies’ platforms is expected to enable fast and accurate identification of meaningful changes in immune-mediated disease activity in order to facilitate effective treatment decisions and patient care.
Kypha CEO Chad Stienin said: “The proprietary technologies and core competencies of each company are perfectly synergistic. Blending them enhances and accelerates the delivery of our products to health care practitioners, researchers and pharmaceutical companies seeking to more precisely assess and monitor immune status dynamics.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Stiening added that acquisition of Biosensia’s facilities and core team in the European Union (EU) will allow in-house product development, test manufacturing and quality control.
In addition, Kypha will be able to continue contract assay development and manufacturing services for Biosensia clients.
Kypha chief scientific officer Martin Schmidt said: “This acquisition reinforces our position as the ideal diagnostic partner for stratifying patient populations and tailoring treatment for each patient suffering from immune mediated conditions.”
Following the closure of the transaction, Biosensia will operate as a wholly-owned subsidiary of Kypha.